Literature DB >> 33432682

Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma.

Grainne d'Ancona1, Joanne E Kavanagh1,2, Jaideep Dhariwal1,2, Andrew P Hearn1,2, Cris Roxas1, Mariana Fernandes1, Linda Green1, Louise Thomson1, Alexandra M Nanzer1,2, David J Jackson1,2, Brian D Kent1,3,4.   

Abstract

Entities:  

Year:  2021        PMID： 33432682     DOI： 10.1111/all.14737

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  4 in total

Review 1.  A pragmatic guide to choosing biologic therapies in severe asthma.

Authors:  Joanne E Kavanagh; Andrew P Hearn; David J Jackson
Journal:  Breathe (Sheff)       Date:  2021-12

2.  Con: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment.

Authors:  Ireti Adejumo; Dominick E Shaw
Journal:  Breathe (Sheff)       Date:  2021-06

3.  Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment.

Authors:  Anna C Murphy; Claire Boddy; Peter Bradding
Journal:  Breathe (Sheff)       Date:  2021-06

Review 4.  Improving adherence in chronic airways disease: are we doing it wrongly?

Authors:  Gráinne d'Ancona; John Weinman
Journal:  Breathe (Sheff)       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.